Personalized versus evidence-based medicine with PET-based imaging

Nature Reviews Clinical Oncology

Volumn 7, Issue 11, 2010, Pages 665-668

  Basu, Sandip ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TRACER; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BURKITT LYMPHOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; EVIDENCE BASED MEDICINE; FALSE POSITIVE RESULT; FEASIBILITY STUDY; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; MEDICINE; MOLECULAR IMAGING; OVERALL SURVIVAL; PATIENT CARE; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR; TREATMENT RESPONSE;

DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; FLUORODEOXYGLUCOSE F18; HUMANS; MOLECULAR BIOLOGY; NEOADJUVANT THERAPY; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS;

EID: 78049465544     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.121     Document Type: Review

References (29)

1. Hutchings, M. & Barrington, S. F. PET/cT for therapy response assessment in lymphoma. J. Nucl. Med. 50 (Suppl. 1), 21S-30S (2009).
2. Basu, S. PET and PET/cT in gastrointestinal stromal tumours: the unanswered questions and the potential newer applications. Eur. J. Nucl. Med. Mol. Imaging 37, 1255-1258 (2010).
3. Torizuka, T et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur. J. Nucl. Med. Mol. Imaging 31, 22-28 (2004).
4. Dührsen, U., Hüttmann, A., Jöckel, K. H. & Müller, S. Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas-the PETAL trial. Leuk. Lymphoma 50, 1757-1760 (2009).
5. 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann. Oncol. 13, 1356-1363 (2002).
6. Mikhaeel, N. G., Hutchings, M., Fields, P A., O'Doherty, M. J. & Timothy, A. R. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann. Oncol. 16, 1514-1523 (2005).
7. 18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J. Clin. Oncol. 25, 3746-3752 (2007).
8. 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 85, 613-618 (2000).
9. Kostakoglu, L. et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J. Nucl. Med. 43, 1018-1027 (2002).
10. Mikhaeel, N. G., Timothy, A. R., O'Doherty, M. J., Hain, S. & Maisey, M. N. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma: comparison with cT. Leuk. Lymphoma 39, 543-553 (2000).
11. Juweid, M. E. et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J. Clin. Oncol. 25, 571-578 (2007).
12. 18F-FDG PET to medicine over 3 decades. J. Nucl. Med. 49, 17N-21N, 37N (2008).
13. Reed, C. E. et al. Results of the American college of Surgeons Oncology Group Z0050 Trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 126, 1943-1951 (2003).
14. Verhagen, A. F. T. et al. FDG-PET in staging lung cancer\how does it change the algorithm? Lung Cancer 44, 175-181 (2004)
15. Enzinger, P C. & Mayer, R. J. Esophageal cancer. N. Engl. J. Med. 349, 2241-2252 (2003).
16. Quon, A. & Gambhir, S. S. FDG-PET and beyond: molecular breast cancer imaging. J. Clin. Oncol. 23, 1664-1673 (2005).
17. Burmeister, B. H. et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol. 6, 659-668 (2005).
18. Rouvelas, I. et al. Survival after surgery for oesophageal cancer: a population-based study. Lancet Oncol. 6, 864-870 (2005).
19. Basu, S. & Alavi, A. Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites? Eur. J. Nucl. Med. Mol. Imaging 34, 604-605 (2007).
20. Basu, S. & Alavi, A. Staging with PET and the "Will rogers" effect: redefining prognosis and survival in patients with cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 1-4 (2008).
21. 18F-FDG PET in oncology. J. Nucl. Med. 49, 480-508 (2008).
22. Weber, W. A. et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J. Clin. Oncol. 21, 2651-2657 (2003).
23. Brucher, B. L. D. M. et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann. Surg. 233, 300-309 (2001).
24. Bombardieri, E. The added value of metabolic maging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment. Eur. J. Nucl. Med. Mol. Imaging 33, 753-758 (2006).
25. Basu, S., Mavi, A., Cermik, T., Houseni, M. & Alavi, A. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology? Mol. Imaging Biol. 10, 62-66 (2008).
26. Winter, M. C. & Hancock, B. W. Ten years of rituximab in NHL Expert Opin. Drug Saf. 8, 223-235 (2009).
27. Basu, S. & Alavi, A. Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer? Eur. J. Nucl. Med. Mol. Imaging 34, 1527-1529 (2007).
28. Kumar, R. et al. Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging. Q. J. Nucl. Med. Mol. Imaging 52, 50-65 (2008).
29. Basu, S., Kumar, R., Rubello, D., Fanti, S. & Alavi, A. PET imaging in neuroendocrine tumors: current status and future prospects. Minerva Endocrinol. 33, 257-275 (2008).